



ZERO TOLERANCE FOR FAILURE

PHARMACISTS FIGHT BACK

Clinical Skills and Competencies Workshop



STATE SHP SOCIETY MEETINGS

South Carolina – Saturday, March 14, 2009

Texas – Friday, April 17, 2009

New York – Friday, May 1, 2009

Louisiana – Friday, May 22, 2009

Arkansas – Thursday, June 11, 2009

Florida – Friday, July 31, 2009

Illinois – Thursday, September 10, 2009

California – Saturday, October 3, 2009

EDUCATIONAL OVERVIEW

Hospital-acquired infections (HAIs) are associated with a high degree of morbidity and mortality, prolonged length of stay, and substantially higher healthcare costs. The economic burden of these infections is further exacerbated in today's environment of greater transparency and accountability by hospitals and non-reimbursement for certain hospital-acquired conditions. In order to help alleviate the clinical and economic costs of HAIs, clinical pharmacists must act as leaders of healthcare teams to ensure appropriate management of these patients. This may include selecting appropriate antimicrobials based on local epidemiology, incorporating optimized dosing regimens, and considering de-escalation of therapy when suitable.

This educational activity provides a clinically focused overview of the issues related to serious bacterial infections in the hospital. This activity will address the challenges clinical pharmacists face when treating HAIs and will include discussion on topics related to bacterial resistance, appropriate antimicrobial selection and dosing, and the pharmacist's role in patient management. An interactive clinical skills workshop will demonstrate how the information gained can be utilized at bedside.

PURPOSE STATEMENT

The purpose of this activity is to educate clinical pharmacists on the challenges associated with HAIs and their role in the management of these patients. This will be accomplished by practical education and discussion of leading issues facing clinical pharmacists as well as the use of a case study workshop to show how to apply this knowledge in the clinical practice setting.

TARGET AUDIENCE

This activity has been developed for clinical pharmacists responsible for the management and prevention of HAIs.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to

- Discuss the prevalence and impact of bacterial resistance in HAIs
- Evaluate antimicrobial dosing strategies that minimize resistance development and achieve optimal clinical outcomes
- Recognize how clinical pharmacists can play an active role in the management of patients with HAIs

ACCREDITATION



Center for Independent Healthcare Education (Center) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Center has assigned 2.0 contact hours (0.2 CEUs) of continuing pharmacy education credit to this activity. Universal Activity Number: 473-999-09-004-L01-P.

This is an Application-based activity.

For questions regarding the accreditation of this activity, please contact Center at [info@jointponsor.com](mailto:info@jointsponsor.com).

PROGRAM AGENDA

Welcome and Introduction

- Defining Failure: 360° Approach

Strategy to Success

- Know Your Enemies: Many Faces of HAIs
- Know Your Armamentarium and How to Use It: Individualize Therapy Through Optimized Dosing

Clinical Skills and Competencies Workshop

Learning by Sharing: Interactive Q&A with Faculty

FACULTY

David S. Burgess, PharmD
San Antonio, Texas

Richard H. Drew, PharmD, MS, BCPS
Durham, North Carolina

Thomas M. File, MD, MACP
Rootstown, Ohio

Debra A. Goff, PharmD
Columbus, Ohio

Joseph F. John, Jr., MD, FACP, FIDSA
Charleston, South Carolina

David P. Nicolau, PharmD, FCCP, FIDSA
Hartford, Connecticut

Michael S. Niederman, MD
Mineola, New York

Robert P. Rapp, PharmD
Lexington, Kentucky

Keith A. Rodvold, PharmD, FCCP, FIDSA
Chicago, Illinois

Jerome J. Schentag, PharmD
Buffalo, New York

OUTCOMES STUDY

This activity is designed to empower clinical pharmacists with practical knowledge so that they can apply what is learned to successfully manage HAIs. To assess the impact on practice performance, the intent to change will be reinforced and its implementation evaluated through an innovative Outcomes Study. This Outcomes Study will be performed in collaboration with the State Societies of Health-System Pharmacists (SHPs) and the Society of Infectious Diseases Pharmacists (SIDP). It will be conducted using pre- and post-survey methodology with actionable "Clinical Pearls" email reminders. Changes in decision-making, guidelines adherence, strategies implementation, and multidisciplinary team approach will be assessed.

Qualitative and quantitative analyses will provide invaluable insight into appropriate management of HAIs and the needs of the State SHP membership. The results of the Outcomes Study will be available on the SIDP and State SHP websites.

INSTRUCTIONS FOR CREDIT

To receive a CE Statement of Credit, participants must register for the activity, document attendance, and complete and return the Post-test, Evaluation, and Credit Application form. A CE Statement of Credit will be mailed within 4 weeks of the activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Center for Independent Healthcare Education (Center) requires faculty, planners, and other individuals who are in a position to control the content of continuing education activities to disclose to the audience any real or apparent conflict of interest related to the activity. All identified conflicts of interest are thoroughly reviewed by Center to ensure fair balance, objectivity, and scientific rigor in all educational activities. The faculty is further required to disclose discussion of off-label uses in their presentations.